Last reviewed · How we verify
Oligomeric Procyanidin Complex
Oligomeric Procyanidin Complex is a Botanical antioxidant, polyphenol Small molecule drug developed by Medical University of South Carolina. It is currently in discontinued development. Also known as: OPC.
Oligomeric procyanidins are plant-derived polyphenols that exert antioxidant and anti-inflammatory effects, potentially inhibiting advanced glycation end product formation.
Oligomeric Procyanidin Complex is a small molecule intervention studied in various conditions, including Lichen Planus, Prostate Cancer, and Preneoplastic Condition, as part of the RiteStart Supplement. It is a component of the RiteStart Personal Nutritional Dietary Study, which is an open-label trial examining the safety and efficacy of this supplement.
At a glance
| Generic name | Oligomeric Procyanidin Complex |
|---|---|
| Also known as | OPC |
| Sponsor | Medical University of South Carolina |
| Drug class | Botanical antioxidant, polyphenol |
| Target | Advanced glycation end products (AGEs), free radicals, inflammatory mediators |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | discontinued |
Mechanism of action
Oligomeric procyanidins (OPCs) are naturally occurring flavonoid compounds found in plant sources such as grape seeds and pine bark. These molecules function primarily as antioxidants, neutralizing free radicals that contribute to cellular damage and aging. In the context of the discontinued Medical University of South Carolina program, OPC was hypothesized to interfere with the formation of advanced glycation end products (AGEs)—harmful compounds formed when glucose binds to proteins, a process implicated in diabetes complications, vascular disease, and cancer progression. The mechanism was thought to involve both direct antioxidant activity and modulation of inflammatory pathways, potentially explaining proposed benefits in energy metabolism and periodontal health. However, the limited clinical evidence and discontinuation of the program suggest that efficacy in human disease was not convincingly demonstrated.
Approved indications
Pipeline indications
- Prostate cancer prevention (AGE manipulation) — Phase 1
- Energy levels in healthy volunteers — Phase 2
- Gingivitis prevention — Phase 4
Common side effects
Key clinical trials
- Effect of MOF on Exercise Blood Pressure (NA)
- RiteStart Personal Nutritional Dietary Study (NA)
- Study on Treatment for Patients With Symptomatic Oral Lichen Planus (NA)
- Treatment Protocols for Patients With Symptomatic Oral Lichen Planus (NA)
- Study of Metformin Plus Oligomeric Procyanidin Complex for Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients (PHASE1)
- Prospective Double-Blind Randomized Controlled Clinical Trial in the Gingivitis Prevention With OPCs (PHASE4)
- Effect of OPC Factor on Energy Levels (PHASE2)
- Cardiovascular Effects of Oligomeric Procyanidins (OPCs) in Smokers (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oligomeric Procyanidin Complex CI brief — competitive landscape report
- Oligomeric Procyanidin Complex updates RSS · CI watch RSS
- Medical University of South Carolina portfolio CI
Frequently asked questions about Oligomeric Procyanidin Complex
What is Oligomeric Procyanidin Complex?
How does Oligomeric Procyanidin Complex work?
Who makes Oligomeric Procyanidin Complex?
Is Oligomeric Procyanidin Complex also known as anything else?
What drug class is Oligomeric Procyanidin Complex in?
What development phase is Oligomeric Procyanidin Complex in?
What does Oligomeric Procyanidin Complex target?
Related
- Drug class: All Botanical antioxidant, polyphenol drugs
- Target: All drugs targeting Advanced glycation end products (AGEs), free radicals, inflammatory mediators
- Manufacturer: Medical University of South Carolina — full pipeline
- Therapeutic area: All drugs in Oncology
- Also known as: OPC
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing